BCDA BioCardia, Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 925741 · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (2025Q4), TTM = sum of the last four quarters
Growth
TTM revenue YoY-100.0%
TTM net income YoY-3.5%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-950.1%
ROA-230.6%
ROIC (approx.)—
Asset turnover0.00x
Leverage & solvency
Liabilities / assets73.8%
Debt / equity0.00x
Current ratio1.12x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.90x
Accruals ratio-22.2%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $0 | $58,000 | $477,000 | $1.35M | $1.01M |
| Cost of revenue | — | — | — | — | $0 |
| Gross profit | — | — | — | — | $1.01M |
| R&D expense | $4.96M | $4.39M | $7.73M | $8.83M | $8.56M |
| SG&A expense | $3.32M | $3.67M | $4.39M | $4.42M | $5.09M |
| Operating income | -$8.28M | -$8.00M | -$11.64M | -$11.90M | -$12.63M |
| Interest expense | — | — | — | — | $0 |
| Income tax | $0 | $0 | $0 | $0 | $0 |
| Net income | -$8.23M | -$7.95M | -$11.57M | -$11.91M | -$12.62M |
| EBITDA | -$8.25M | -$7.93M | -$11.56M | -$11.82M | -$12.57M |
| EPS (basic) | -1.23 | -2.90 | -8.19 | -0.67 | -0.75 |
| EPS (diluted) | — | — | — | — | -0.75 |
| Weighted avg. shares (diluted) | — | — | — | — | 16.92M |
| Balance sheet | |||||
| Cash & equivalents | $2.50M | $2.37M | $1.10M | $7.36M | $12.87M |
| Receivables | $20,000 | $0 | $63,000 | $201,000 | $147,000 |
| Current assets | $2.73M | $2.62M | $1.46M | $7.86M | $13.48M |
| PP&E, net | $16,000 | $33,000 | $94,000 | $170,000 | $182,000 |
| Total assets | $3.41M | $3.72M | $2.99M | $9.79M | $15.72M |
| Current liabilities | $2.43M | $2.32M | $3.61M | $3.58M | $3.71M |
| Total liabilities | $2.52M | $2.89M | $4.59M | $4.90M | $5.34M |
| Shareholders' equity | $895,000 | $837,000 | -$1.60M | $4.89M | $10.38M |
| Shares outstanding | 10.76M | 4.60M | 1.58M | 20.08M | 16.87M |
| Cash flow statement | |||||
| Operating cash flow | -$7.44M | -$7.89M | -$9.97M | -$10.56M | -$10.37M |
| Capital expenditure | $7,000 | $6,000 | $12,000 | $70,000 | $116,000 |
| Free cash flow | -$7.44M | -$7.89M | -$9.99M | -$10.63M | -$10.48M |
| Investing cash flow | -$7,000 | -$6,000 | -$12,000 | -$70,000 | -$116,000 |
| Financing cash flow | $7.57M | $9.16M | $3.73M | $5.12M | $1.95M |
| Depreciation & amortization | $24,000 | $67,000 | $84,000 | $82,000 | $60,000 |
| Stock-based compensation | $430,000 | $741,000 | $1.03M | $1.18M | $1.66M |
Free plan shows the latest 5 periods; Pro shows all 16 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.